The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.
Solana, founded in 2017 by former Illumina employees, has launched hundreds of products, including DNA sequencing solutions.
10x plans to use Epinomics' epigenomic technology to launch a single-cell ATAC solution on its Chromium platform by the end of the year.
Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.
According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.
Diagenode said the deal will bolster its suite of epigenomics services and platforms, as well as enhance its epigenetic biomarker discovery efforts.
The acquisition will enable Tecan to expand into the genomics space by coupling NuGen's NGS sample prep kits with its own laboratory automation products.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.